Patients with intrahepatic cholangiocarcinoma (IHC) have relatively aggressive tumors, and the prognosis for most of these patients is dismal. Surgery is the only option that can offer potential cure, but only an estimated 20-25 % are amenable to resection. Down-staging conventional chemotherapy has a relatively low response rate (< 50 %). Patients will be included into the respective treatment arms based on their tumour characteristics and disease stage, but also based on their ability/preferences, as HAI-FUDR/DEX requires going to Oslo every fortnight for the duration of the treatment and SIRT has some limitations regarding tumour distribution.
Data from the MSKCC has suggested a clinically relevant benefit from adding intrahepatic chemotherapy to systemic therapy. HAI-FUDR/DEX is not approved in Norway and can only be evaluated in a protocolized trial. Given the risk of distant disease progression with IHC, the addition of conventional systemic chemotherapy makes good clinical sense, and data from MSKCC supports this approach. SIRT is another modality also applied trans-arterially and directly into the tumour. This treatment is approved in Norway and available in Bergen and in Oslo. It is far less cumbersome to deliver and maintain than HAI-FUDR/DEX. The efficacy and safety of the two treatment groups, HAI-FUDR/DEX and SIRT, will be compared in a parallel cohort (non-randomized) design

Start Date13 Feb 2024

Sponsor / Collaborator

Oslo universitetssykehus HF

NCT05863195 / RecruitingPhase 3IIT

A Randomized Phase III Study of Systemic Therapy With or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial

This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the liver (liver metastases) and cannot be removed by surgery (unresectable). HAI uses a catheter to carry a tumor-killing chemotherapy drug called floxuridine directly into the liver. HAI is already approved by the Food and Drug Administration (FDA) for use in metastatic colorectal cancer to the liver, but it is only available at a small number of hospitals, and most of the time it is not used until standard chemotherapy stops working. Standard chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding HAI to standard chemotherapy may be effective in shrinking or stabilizing unresectable colorectal liver metastases.

Start Date19 Oct 2023

Sponsor / Collaborator

ECOG-ACRIN Medical Research Foundation, Inc.

[+1]

NCT05286814 / RecruitingPhase 2IIT

Phase II Study Evaluating the Efficacy of PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Background:
One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment. The drug triggers the immune system to fight cancer.
Objective:
To see if treatment with HAIPs to deliver liver-directed chemotherapy in combination with PDS01ADC is effective for certain cancers.
Eligibility:
People aged 18 and older who have cancer of the bile ducts that is only in the liver, or colorectal cancer that has spread to the liver.
Design:
Participants will be screened with:
Medical history
Physical exam
Blood tests
Pregnancy test (if needed)
Tumor biopsy (if needed)
Electrocardiogram
Computed tomography (CT) scans
Participants will have an abdominal operation. A catheter will be placed into an artery that feeds blood to the liver. The catheter will then be attached to the HAIP. The HAIP will lay under the skin on the left side of the abdomen.
Participants will have chemotherapy drugs or heparin with saline infused into the HAIP every 2 weeks. PDS01ADC will be injected under the skin every 4 weeks. They will get systemic chemotherapy through an IV or mediport every 2 weeks. They will receive this treatment until their cancer gets worse or they have bad side effects.
Participants will have 2 study visits each month. They will have CT scans every 8 weeks. At visits, they will repeat some screening tests.
Participants will have a follow-up visit 1 month after treatment ends. Then they will be contacted every 6 months for 5 years.

Start Date24 Oct 2022

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Floxuridine

100 Translational Medicine associated with Floxuridine

100 Patents (Medical) associated with Floxuridine

2,158

Literatures (Medical) associated with Floxuridine

01 Dec 2024·VIROLOGY

5-Bromo-2′-deoxyuridine inhibits African swine fever virus (ASFV) replication via interfering viral DNA replication and suppressing the formation of viral factories

Article

Author: Lin, Qisheng ; Su, Guanming ; Luo, Ding ; Su, Guangmin ; Long, Feixiang ; Ou, Weixin ; Su, Guoming ; Long, Feixaing ; Chen, Jianxin ; Liu, Zexin ; Liu, Jinyi

African swine fever (ASF), caused by ASF virus (ASFV), represents one of the most economically important viral infectious diseases in swine industry worldwide. So far there is no vaccine or antiviral drug for controlling ASF pandemics. In the present study, we assessed inhibition of six nucleoside analogues against ASFV replication in ex vivo primary porcine alveolar macrophages (PAMs), including the first approved antiviral drug idoxuridine. Our results showed that, out of the assessed six compounds, 5-Bromo-2'-Deoxyuridine (5-BrdU, an analog of idoxuridine), exhibited the strongest inhibition on the replication of ASFV in PAMs with a 50% inhibitory concentration (IC₅₀) value of 2.9 μM and a low cytotoxicity (CC₅₀ > 270 μM). Moreover, we showed that 5-BrdU interferes with ASFV DNA replication by incorporating into viral replicating DNA molecules as a competitive substrate for deoxythymidine, ultimately inhibiting the formation of ASFV viral factories. Altogether, our findings suggest that 5-BrdU could serve as a promising therapeutic agent for combating ASFV infection.

01 Dec 2024·NEOPLASIA

ARID1A loss sensitizes colorectal cancer cells to floxuridine

Article

Author: Han, Zelong ; Song, Yijiang ; Wang, Zihuan ; Zhang, Xu ; Lu, Jingyi ; Wu, Changjie ; Pan, Lei ; Xiang, Cheng ; Yu, Yingnan ; He, Yilin ; Peng, Wenxuan ; Wang, Kejin ; Liu, Side ; Wang, Zhen

The loss-of-function mutation of AT-rich interactive domain 1A (ARID1A) frequently occurs in various types of cancer, making it a promising therapeutic target. In the present study, we performed a screening of an FDA-approved drug library in ARID1A isogenic colorectal cancer (CRC) cells and discovered that ARID1A loss sensitizes CRC cells to floxuridine (FUDR), an antineoplastic agent used for treating hepatic metastases from CRC, both in vivo and in vitro. As a pyrimidine analogue, FUDR induces DNA damage by inhibiting thymidylate synthase (TS) activity. ARID1A, as a regulator of DNA damage repair, when lost, exacerbates FUDR-induced DNA damage, leading to increased cell apoptosis. Specifically, ARID1A deficiency impairs DNA damage repair by downregulating Chk2 phosphorylation, thereby sensitizing cancer cells to FUDR. Notably, we found that FUDR exhibited increased sensitivity in ARID1A-deficient cells compared to 5-fluorouracil (5-FU), a commonly used anticancer drug for CRC. This suggests that FUDR is superior to 5-FU in treating ARID1A-deficient CRC. In conclusion, ARID1A loss significantly heightens sensitivity to FUDR by promoting FUDR-induced DNA damage in CRC. These findings offer a novel therapeutic approach for the treatment of CRC characterized by ARID1A loss-of-function mutations.

04 Nov 2024·MOLECULAR PHARMACEUTICS

RNA Nanotechnology for Codelivering High-Payload Nucleoside Analogs to Cancer with a Synergetic Effect

Article

Author: Lee, Wen-Jui ; Cheng, Tzu-chun ; Chen, Li-Ching ; Li, Xin ; Ho, Yuan-Soon ; Jin, Kai ; Guo, Peixuan ; Liao, You-Cheng

Nucleoside analogs are potent inhibitors for cancer treatment, but the main obstacles to their application in humans are their toxicity, nonspecificity, and lack of targeted delivery tools. Here, we report the use of RNA four-way junctions (4WJs) to deliver two nucleoside analogs, floxuridine (FUDR) and gemcitabine (GEM), with high payloads through routine and simple solid-state RNA synthesis and nanoparticle assembly. The design of RNA nanotechnology for the co-delivery of nucleoside analogs and the chemotherapeutic drug paclitaxel (PTX) resulted in synergistic effects and high efficacy in the treatment of Triple-Negative Breast Cancer (TNBC). The 4WJ-drug complexes were confirmed to have efficient tumor spontaneous targeting and no toxicity because the motility of RNA nanoparticles has been previously shown to enable these RNA-drug complexes to spontaneously accumulate in tumor blood vessels. The negative charge of RNA enables those RNA complexes that are not targeted to tumor vasculature to circulate in the blood and enter the urine through the kidney glomerulus, without accumulating in organs, therefore being nontoxic. Drug incorporation into RNA 4WJ can be precisely controlled with a defined loading amount, location, and ratio. The incorporation of nucleoside analogs into 4WJ only requires one step using nucleoside analogue phosphoramidites during solid-phase RNA synthesis, without the need for additional conjugation and purification processes.

News (Medical) associated with Floxuridine

25 Nov 2024

·www.prnewswire.com

Boston Scientific Announces Agreement to Acquire Intera Oncology® Inc.

Acquisition to expand interventional oncology offerings with complementary therapy to treat liver-dominant metastases MARLBOROUGH, Mass., Nov. 25, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Intera Oncology® Inc., a privately held medical device company that provides the Intera 3000 Hepatic Artery Infusion Pump and floxuridine – a chemotherapy drug – both of which are approved by the U.S. Food and Drug Administration. The Intera 3000 pump is used to administer hepatic artery infusion (HAI) therapy to treat tumors in the liver primarily caused by metastatic colorectal cancer. There are approximately 1.4 million people in the U.S. living with primary colorectal cancer, and more than 150,000 new cases are diagnosed each year.i For nearly 25% of these patients, the cancer will spread to the liver during their illness.ii In patients who receive HAI therapy to treat their cancer, the Intera 3000 pump is implanted under the skin and a connected catheter is placed in the hepatic artery, which supplies the liver with oxygenated blood. The pump then provides a continuous flow of floxuridine directly into the liver to treat tumors that have metastasized, most commonly from the colon. "Liver cancer is a leading cause of cancer-related death, and we are committed to providing meaningful solutions to safely and effectively treat various forms of this disease with minimal systemic side effects and improved outcomes for patients," said Peter Pattison, president, Interventional Oncology and Embolization, Boston Scientific. "Interest in HAI therapy has grown in the oncology community given improved techniques, positive clinical results and ongoing trials. We believe this acquisition will enable us to provide a more comprehensive set of solutions to physicians and their patients to treat both primary and metastatic forms of liver cancer." The Intera 3000 pump is the only constant flow implantable pump for HAI therapy approved in the United States. The safety and effectiveness of the Intera 3000 pump is supported by data from randomized controlled trials demonstrating the clinical benefits of HAI therapy for patients with unresectable colorectal metastases to the liver, both prior to and following resection. Data from these trials have highlighted that HAI therapy significantly improves tumor response, time to progression and overall survival compared to systemic chemotherapy,iii,iv,v and that combining HAI with systemic chemotherapy may lead to extended survival and higher conversion-to-resection rates in both chemotherapy-naïve and previously treated patients.vi,vii Current Phase II and III studies are exploring HAI therapy use in larger patient groups for first-line, second-line and post-surgery adjuvant treatments. Boston Scientific expects to complete the transaction in the first half of 2025, subject to closing conditions. The transaction is expected to have an immaterial impact on adjusted earnings per share in 2025 and is expected to be more dilutive on a GAAP basis due to acquisition-related net charges and amortization expense. Specific terms of the transaction have not been disclosed. About Boston Scientific Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at and connect on LinkedIn and X, formerly Twitter. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, the financial and business impact of the transaction and the anticipated benefits of the transaction, the closing of the transaction and the timing thereof, and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the forward-looking statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Factors that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; market competition for our products; expected procedural volumes; new product introductions; demographic trends; the closing and integration of acquisitions, including our ability to achieve the anticipated benefits of the proposed transaction and successfully integrate Intera's operations; business disruptions (including disruptions in relationships with employees, customers and suppliers) following the announcement and/or closing of the proposed transaction; intellectual property; litigation; financial market conditions; future business decisions made by us and our competitors; the conditions to the completion of the proposed transaction, including the receipt of any required regulatory approvals and clearances, may not be satisfied at all or in a timely manner; and the closing of the proposed transaction may not occur or may be delayed. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release. CONTACTS: Blake Rouhani Media Relations +1 (763) 494-2268 [email protected] Jon Monson Investor Relations +1 (508) 683-5450 [email protected] i Colorectal Cancer — Cancer Stat Facts ii Colorectal liver metastases: Current management and future perspectives - PMC iii Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis - PubMed iv Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case-Control Study - PubMed v Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481) - PubMed vi Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential - PubMed vii ASO Visual Abstract: Combined Hepatic Artery Infusion Pump and Systemic Chemotherapy in the Modern Era for Chemotherapy-Naive Patients with Unresectable Colorectal Liver Metastases | Annals of Surgical Oncology SOURCE Boston Scientific Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Acquisition

100 Deals associated with Floxuridine

External Link

KEGG	Wiki	ATC	Drug Bank
D04197	Floxuridine	L01BC09	DB00322

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Breast Cancer	CN	Hanhui Pharmaceutical Co. Ltd. (China)	01 Jan 2001
Esophageal Carcinoma	CN	Hanhui Pharmaceutical Co. Ltd. (China)	01 Jan 2001
Liver Cancer	CN	Hanhui Pharmaceutical Co. Ltd. (China)	01 Jan 2001
Lung Cancer	CN	Hanhui Pharmaceutical Co. Ltd. (China)	01 Jan 2001
Rectal Cancer	CN	Hanhui Pharmaceutical Co. Ltd. (China)	01 Jan 2001
Stomach Cancer	CN	Hanhui Pharmaceutical Co. Ltd. (China)	01 Jan 2001
Colorectal Cancer	US	Hospira, Inc.	18 Dec 1970

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04251715 (HELIX-1, ASCO_GI2024) Manual	Phase 2	Unresectable Intrahepatic Cholangiocarcinoma First line	5	mFOLFIRINOX + floxuridine+mFOLFIRI	roxmdcvlcn(cogcmupcwz) = vesbniqpda xqzafuftvq (drxigwnwbp ) View more	Positive	18 Jan 2024
NCT03500874 (HARVEST, ASCO2023)	Phase 3	Colorectal Liver Metastases Adjuvant	-	Systemic FOLFOX only	duqpofgcok(lcbmtsfsuq) = tojhlejcgo kbixkbhdqk (shehrxiqap )	Negative	31 May 2023
NCT03500874 (HARVEST, ASCO2023)	Phase 3	Colorectal Liver Metastases Adjuvant	-	Systemic FOLFOX plus HAI FUDR	duqpofgcok(lcbmtsfsuq) = nrvxglmnsn kbixkbhdqk (shehrxiqap )	Negative	31 May 2023
NCT00645710 (CTgov)	Phase 1/2	Recurrent Colon Cancer \| Rectal Cancer \| Liver metastases ... View more	16	1- FUdR (Dose Level 1- FUdR 0.10 mg/kg/Day)	zlhcnopryy(qlwbwdnezs) = gujqapguur aujqsujira (rdrwxorhaf, zfbcfknnny - ujjcxtiwdq) View more	-	28 Mar 2019
NCT00645710 (CTgov)	Phase 1/2		16	2 - FUdR (Dose Level 2 - FUdR 0.15 mg/kg/Day)	zlhcnopryy(qlwbwdnezs) = apldxdsqet aujqsujira (rdrwxorhaf, afdmiregqe - pfbepdodhp) View more	-	28 Mar 2019
NCT01692704 (ASCO_GI2018)	Phase 1/2	Unresectable Intrahepatic Cholangiocarcinoma	12	Systemic intravenous gemcitabine + cisplatin + hepatic arterial infusion with floxuridine	xulgcddwma(ejidgqppog) = serqhkumla osydvcegsp (kzbxeruety ) View more	-	26 Feb 2018
NCT00587067 (CTgov)	Phase 2	Unresectable Hepatocellular Carcinoma	34	Floxuridine+Dexamethasone	sscxqjqmiw(piidkafjzu) = dgzzydejgy vgwrlzpscc (hbzglrxnwe, qkjjfduxqw - hitazzwpfu) View more	-	04 Aug 2017
NCT00448760 (ASCO_GI2016)	Phase 2	Locally Advanced Gastroesophageal Junction Adenocarcinoma Neoadjuvant \| Adjuvant	29	Floxuridine, Leucovorin, Oxaliplatin, and Docetaxel (FLOD)	mxzffbssmo(zvtjqkxfjc) = uvxlhvppcm amaaqwkhzy (jdkqbulinz ) View more	Positive	01 Feb 2016
NCT00448682 (CTgov)	Phase 2	Metastatic gastric adenocarcinoma	25	Leucovorin+Docetaxel+FUdR+Oxaliplatin	rlkuhasamm(zpslfhojwm) = gpxocitiap rdvhdtltsz (wfuzegjtqs, dwxggvnsqo - qjfbjyekoe) View more	-	13 May 2013
NCT00449163 (CTgov)	Phase 2	Metastatic Colorectal Carcinoma	25	Leucovorin+Floxuridine+Bevacizumab+Irinotecan	tonckhoiwa(vrbazdbwql) = lukjzpgppx jcerzzowwz (yzubifywvb, aspzavunue - jnlaciobhw) View more	-	28 Feb 2013
ASCO_GI2012	Phase 1	Neuroendocrine Tumors	19	Hepatic arterial floxuridine/leucovorin/streptozotocin	xpsanzptvg(wlfuvkhqqf) = twtywtwmhn hmbhfyuokt (zarxwopckh, 8.4 - 45.4) View more	-	01 Feb 2012
ASCO_GI2012	Phase 1	Neuroendocrine Tumors	19	Hepatic arterial floxuridine/leucovorin	xpsanzptvg(wlfuvkhqqf) = oiftpwlqra hmbhfyuokt (zarxwopckh, 3.4 - 67.8)	-	01 Feb 2012

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis